Publications

Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV

Post Date: 
2019-12-20
Publication: 
Lancet HIV
Lancet HIV: Dr. Bob Bollinger and colleagues discuss the urgent need and opportunity to include activity against Hepatitis B in formulations of long-acting drugs for HIV prevention and treatment

Transcriptomic profiles of confirmed pediatric tuberculosis patients and household contacts identifies active tuberculosis, infection, and treatment response among Indian children

Post Date: 
2019-12-04
   |   
Clinical Sites: 
Publication: 
Journal of Infectious Diseases
Journal of Infectious Diseases: Gene expression profiles among Indian children with confirmed TB were distinct from those of adults, highlighting the importance of including distinct populations in differential gene expression models

Evaluating the Concordance of Clinician Antiretroviral Prescribing Practices and HIV-ASSIST, an Online Clinical Decision Support Tool

Post Date: 
2019-12-02
   |   
Countries: 
Publication: 
Journal of General Internal Medicine
Recent studies have shown that more than half of HIV care is provided by primary care practitioners.However, clinicians with experience and expertise in HIV medicine are declining.

A parsimonious host inflammatory biomarker signature predicts incident TB and mortality in advanced HIV

Post Date: 
2019-11-25
Publication: 
Clinical Infectious Diseases
BACKGROUND: People with advanced HIV (CD4<50) remain at high risk of TB or death despite the initiation of antiretroviral therapy. We aimed to identify immunological profiles that were most predictive of incident TB disease and death. METHODS: The REMEMBER randomized clinical trial enrolled 850...

Lipid mediators of inflammation and resolution in individuals with tuberculosis and tuberculosis-diabetes

Post Date: 
2019-11-11
Publication: 
Prostaglandins and Other Lipid Mediators
Individuals with concurrent tuberculosis (TB) and Type 2 diabetes (DM) have a higher risk of adverse outcomes. To better understand potential immunological differences, we utilized a comprehensive panel to characterize pro-inflammatory and pro-resolving (i.e., mediators involved in the resolution...

MAL adaptor (TIRAP) S180L polymorphism and severity of disease among tuberculosis patients

Post Date: 
2019-10-31
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
Infection, Genetics, and Evolution
Infection, Genetics, and Evolution : We investigated the association of TIRAP variants with severity of TB disease and IP-10 production in humans, which may be useful in predicting poor clinical outcome

Incidence of tuberculosis in HIV-infected adults on first- and second-line antiretroviral therapy in India

Post Date: 
2019-10-29
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
BMC Infectious Diseases
In this study among people living with HIV, Akshay Gupte and colleagues found that the risk of acquiring tuberculosis was higher in those receiving first-line antiretrovial therapy versus those receiving second-line medications.

Isoniazid Preventive Therapy and Pregnancy Outcomes in Women Living With Human Immunodeficiency Virus in the Tshepiso Cohort

Post Date: 
2019-10-21
Publication: 
Clinical Infectious Disease
Background Both pregnancy and human immunodeficiency virus (HIV) increase the risk of tuberculosis disease, which results in poor maternal, pregnancy, and infant outcomes. Isoniazid preventive therapy (IPT) reduces mortality among individuals living with HIV in high-burden settings but has recently...

Isoniazid preventive therapy in HIV-infected pregnant and postpartum women

Post Date: 
2019-10-03
   |      |   
Clinical Sites: 
Publication: 
New England Journal of Medicine
New England Journal of Medicine: Dr. Amita Gupta and colleagues found that the current standard of care given to HIV+ pregnant women to prevent TB should wait until 12 weeks after delivery. The study underscores the need to include pregnant women in clinical trials.

Development and validation of HIV-ASSIST, an online, educational, clinical decision support tool to guide patient-centered ARV regimen selection

Post Date: 
2019-10-01
   |   
Countries: 
Publication: 
JAIDS Journal of Acquired Immune Deficiency Syndromes
Background: Multiple antiretroviral (ARV) regimens are effective at achieving HIV viral suppression, but differ in pill burden, side effects, barriers to resistance, and impact on comorbidities. Current guidelines advocate for an individualized approach to ARV regimen selection, but synthesizing...

Challenges in conducting trials for pediatric tuberculosis meningitis: lessons learned in the field

Post Date: 
2019-10-01
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
International Journal of Tuberculosis and Lung Disease
International Journal of Tuberculosis and Lung Disease: Researchers describe the challenges associated with conducting the first randomized clinical trial of antimicrobial agents in pediatric tuberculosis meningitis.

Delays and barriers to early treatment initiation for childhood tuberculosis in India

Post Date: 
2019-10-01
Publication: 
International Journal of Tuberculosis and Lung Disease
BACKGROUND: India accounts for 27% of global childhood tuberculosis (TB) burden. Understanding barriers to early diagnosis and treatment in children may improve care and outcomes. METHODS: A cross-sectional study was performed among 89 children initiated on anti-TB treatment from a public hospital...

Delamanid central nervous system pharmacokinetics in tuberculous meningitis in rabbits and humans

Post Date: 
2019-09-23
   |   
Clinical Sites: 
Publication: 
Antimicrobial Agents and Chemotherapy
Central nervous system tuberculosis (TB) is devastating and affects vulnerable populations. Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculous meningitis (TBM) specifically are nearly uniformly fatal, with little information being available to guide the treatment of...

Re: A Shorter Regimen for Rifampin-Resistant Tuberculosis

Post Date: 
2019-09-12
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
New England Journal of Medicine
Dr. Jeff Tornheim and colleagues respond to an NEJM article about shorter course TB treatment.

Vitamin D status and risk of incident tuberculosis disease: A nested case-control study, systematic review, and individual-participant data meta-analysis

Post Date: 
2019-09-11
Publication: 
PLoS Medicine
Background: Few studies have evaluated the association between preexisting vitamin D deficiency and incident tuberculosis (TB). We assessed the impact of baseline vitamins D levels on TB disease risk. Methods and findings: We assessed the association between baseline vitamin D and incident TB in a...

Use of smartphone-based video Directly Observed Therapy (vDOT) in tuberculosis care: Single-arm, prospective feasibility study

Post Date: 
2019-08-30
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
Journal of Medical Internet Research
Video-based monitoring is increasingly used as an efficient and low cost alternative to in-person observation and monitoring of TB patients. It showed promise in the high TB setting of India, too.

Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons

Post Date: 
2019-08-15
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
PLOS Medicine
PLOS Medicine: Dr. Amita Gupta and colleagues discuss the scientific and ethical basis for including pregnant and lactation women, children, and HIV+ patients in tuberculosis therapeutic clinical trials.

A tuberculosis-free world: is it a delusion?

Post Date: 
2019-08-12
Publication: 
The Lancet
The Lancet: Dr. Sachin Atre's correspondence questions progress and global commitment toward TB elimination.

Smoking, alcohol use disorder and tuberculosis treatment outcomes: A dual co-morbidity burden that cannot be ignored

Post Date: 
2019-07-31
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
PLoS One
BACKGROUND: More than 20% of tuberculosis (TB) disease worldwide may be attributable to smoking and alcohol abuse. India is the second largest consumer of tobacco products, a major consumer of alcohol particularly among males, and has the highest burden of TB globally. The impact of...

Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study

Post Date: 
2019-07-29
   |   
Countries: 
   |   
Clinical Sites: 
Publication: 
Lancet HIV
BACKGROUND: Antiretroviral therapy (ART) management is challenging for individuals in resource-limited settings presenting for third-line treatment because of complex resistance patterns, partly due to reduced access to viral load monitoring. We aimed to evaluate use of newer...

Pages